Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Fibrolamellar carcinoma (FLC) is a rare liver cancer primarily affecting young adults.
• Current treatment options for recurrent or unresectable FLC are limited, lacking standardized systemic therapies.

Purpose of the Study:

• To investigate the immune microenvironment of FLC by examining key immune-checkpoint pathways.
• To assess the expression of PD-1, PD-L1, B7-H3, IDO-1, and LAG3 in relation to CD8+ cytotoxic T-lymphocyte density.

Main Methods:

• Analysis of 32 FLC tumor specimens using immunohistochemistry (IHC).
• Staining for PD-L1, CD8, PD-1, IDO, LAG3, and B7-H3.
• Evaluation of immune-checkpoint expression in tumor cells, tumor-infiltrating lymphocytes (TILs), and tumor-associated macrophages (TAMs).

Main Results:

• Sixty-three percent of FLC cases showed membranous PD-L1 expression on tumor cells.
• Nearly 70% of cases had PD-L1+ TILs/TAMs, with myeloid-derived cells being a major component.
• B7-H3 expression was observed in 40% of tumor zones and 91% of TILs/TAMs.
• IDO and PD-1 expression were highest at the tumor interface.
• B7-H3 or IDO expression correlated with increased CD8+ T-cell density.

Conclusions:

• A significant proportion of FLC cases exhibit an adaptive immune-resistance pattern characterized by robust PD-1, PD-L1, B7-H3, and IDO expression.
• These findings provide a rationale for targeting these immune-checkpoint pathways in FLC treatment strategies.